Literature DB >> 2843425

Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression.

S J Triezenberg1, R C Kingsbury, S L McKnight.   

Abstract

Mature virions of herpes simplex virus type 1 contain an activating factor that primes transcription from the five virally encoded immediate early (IE) genes. This activator is specified by a 65-kD polypeptide termed VP16. The action of VP16 is mediated through cis-regulatory elements located in regions adjacent to each IE gene. Although VP16 is normally introduced into cells by infecting virions, its trans-activating function can also be observed by cotransfecting cells with a plasmid that encodes VP16 along with a reporter gene driven by IE cis-regulatory sequences. We have used such an assay to examine the function of mutant forms of VP16. Our results provide tentative identification of two domains of VP16 that are crucial to its role in the induction of IE gene expression. One domain is located within the carboxy-terminal 78 amino acids of VP16 and is characterized by its acidity. Another domain, located in a more amino-terminal region of the protein, appears to tailor the specificity of VP16 for IE genes. According to the results presented in this and the accompanying paper, we predict that VP16 achieves IE gene specificity via protein: protein, rather than protein: DNA, interaction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843425     DOI: 10.1101/gad.2.6.718

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  299 in total

1.  Target selectivity of bicoid is dependent on nonconsensus site recognition and protein-protein interaction.

Authors:  C Zhao; V Dave; F Yang; T Scarborough; J Ma
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 renders expression of the immediate-early genes almost entirely dependent on ICP0.

Authors:  K L Mossman; J R Smiley
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Mapping the termini and intron of the spliced immediate-early transcript of equine herpesvirus 1.

Authors:  R N Harty; C F Colle; F J Grundy; D J O'Callaghan
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

4.  The VP16 paradox: herpes simplex virus VP16 contains a long-range activation domain but within the natural multiprotein complex activates only from promoter-proximal positions.

Authors:  M Hagmann; O Georgiev; W Schaffner
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 produces a phenotype similar to that of the in1814 linker insertion mutation.

Authors:  J R Smiley; J Duncan
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Differences in determinants required for complex formation and transactivation in related VP16 proteins.

Authors:  M Grapes; P O'Hare
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Activation of yeast polymerase II transcription by herpesvirus VP16 and GAL4 derivatives in vitro.

Authors:  D I Chasman; J Leatherwood; M Carey; M Ptashne; R D Kornberg
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

8.  Interaction of HCF-1 with a cellular nuclear export factor.

Authors:  Shahana S Mahajan; Markus M Little; Rafael Vazquez; Angus C Wilson
Journal:  J Biol Chem       Date:  2002-09-15       Impact factor: 5.157

9.  Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro.

Authors:  J I Cohen; K Seidel
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  The ability to associate with activation domains in vitro is not required for the TATA box-binding protein to support activated transcription in vivo.

Authors:  W P Tansey; W Herr
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.